Polina Shindiapina, MD
Academic Title: Assistant Professor in the College of Medicine
Research Program: Leukemia and Hematologic Malignancies
About Me
More info forI am a hematologist who specializes in treating patients diagnosed with blood disorders, such as leukemia, lymphoma and sickle cell disease. This extends to my research as a member of the Leukemia Research Program at the OSUCCC – James. Some of my recent projects include a study of the incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies and the comparative analysis of immune reconstitution in HIV-positive recipients of allogeneic and autologous stem cell transplants. Additionally, I have authored or co-authored several articles in well-respected publications, including Leukemia, Therapeutic Advances in Hematology and British Journal of Haematology.
Clinical Expertise
More info for- Anemia, Sickle Cell
- Lymphomas
- Leukemia
Where I See Patients
More info forThe Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
460 W. 10th Ave. Columbus, Ohio 43210 800-293-5066 Location InformationEducation & Training
More info forResidency - Internal Medicine
- Dartmouth-Hitchcock Medical Center
1 Medical Center Dr, Lebanon, NH
Medical School
- Geisel School Of Medicine At Dartmouth
1 Rope Ferry Rd, Hanover, NH
Fellowship - Hematology
- Ohio State University Wexner Medical Center
700 Ackerman Rd, Columbus, OH
Fellowship - Hematology & Oncology
- Ohio State University Wexner Medical Center
700 Ackerman Rd, Columbus, OH
- Dartmouth-Hitchcock Medical Center
Academic Office & Contact Information
More info forAcademic Office:
320 W 10th Ave
Columbus, Ohio 43210-1280Email:
shindiapina.1@osu.eduPublications
More info forNovember 1, 2023Single-center study of outcomes of patients with hairy cell leukemia who contracted SARS-CoV-2.
Annunzio K, Ozga M, Huang Y, Anghelina M, Bhat SA, Blachly JS, Grever MR, Lozanski G, Neal J, Shindiapina P, Rogers KA
EJHaem
June 3, 2023Follicular Helper and Regulatory T Cells Drive the Development of Spontaneous Epstein-Barr Virus Lymphoproliferative Disorder.
Ahmed EH, Lustberg M, Hale C, Sloan S, Mao C, Zhang X, Ozer HG, Schlotter S, Smith PL, Jeney F, Chan WK, Harrington BK, Weigel C, Brooks E, Klimaszewski HL, Oakes CC, Abebe T, Ibrahim ME, Alinari L, Behbehani GK, Shindiapina P, Caligiuri MA, Baiocchi RA
Cancers (Basel)
February 24, 2023A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma.
Hanel W, Shindiapina P, Bond DA, Sawalha Y, Epperla N, Voorhees T, Welkie RL, Huang Y, Behbehani GK, Zhang X, McLaughlin E, Chan WK, Brammer JE, Jaglowski S, Reneau JC, Christian BA, William BM, Cohen JB, Baiocchi RA, Maddocks K, Blum KA, Alinari L
Cancers (Basel)
June 13, 2022Recent Advances in the Management of Relapsed and Refractory Peripheral T-Cell Lymphomas.
Braunstein Z, Ruiz M, Hanel W, Shindiapina P, Reneau JC, Brammer JE
J Pers Med
May 10, 2022Extranodal Natural Killer/T-Cell Lymphomas: Current Approaches and Future Directions.
Reneau JC, Shindiapina P, Braunstein Z, Youssef Y, Ruiz M, Farid S, Hanel W, Brammer JE
J Clin Med
May 26, 2021Targeted Delivery of BZLF1 to DEC205 Drives EBV-Protective Immunity in a Spontaneous Model of EBV-Driven Lymphoproliferative Disease.
Ahmed EH, Brooks E, Sloan S, Schlotter S, Jeney F, Hale C, Mao C, Zhang X, McLaughlin E, Shindiapina P, Shire S, Das M, Prouty A, Lozanski G, Mamuye AT, Abebe T, Alinari L, Caligiuri MA, Baiocchi RA
Vaccines (Basel)
January 1, 2021Immune Recovery Following Autologous Hematopoietic Stem Cell Transplantation in HIV-Related Lymphoma Patients on the BMT CTN 0803/AMC 071 Trial.
Shindiapina P, Pietrzak M, Seweryn M, McLaughlin E, Zhang X, Makowski M, Ahmed EH, Schlotter S, Pearson R, Kitzler R, Mozhenkova A, Le-Rademacher J, Little RF, Akpek G, Ayala E, Devine SM, Kaplan LD, Noy A, Popat UR, Hsu JW, Morris LE, Mendizabal AM, Krishnan A, Wachsman W, Williams N, Sharma N, Hofmeister CC, Forman SJ, Navarro WH, Alvarnas JC, Ambinder RF, Lozanski G, Baiocchi RA
Front Immunol
November 19, 2020Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia.
Khountham S, Shindiapina P, Mo X, Lachowiez C, Wiczer T, Mousa L, Rogers KA, Andritsos LA, Woyach JA, Byrd JC, Spurgeon SE, Awan FT
Leuk Lymphoma
October 13, 2020Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome.
Kittai AS, Bond DA, William B, Saad A, Penza S, Efebera Y, Larkin K, Wall SA, Choe HK, Bhatnagar B, Vasu S, Brammer J, Shindiapina P, Long M, Mims A, O'Donnell L, Bhat SA, Rogers KA, Woyach JA, Byrd JC, Jaglowski SM
Blood Adv
Consulting and Related Relationships
More info forAt The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 09/30/2024, Dr. Shindiapina has reported no relationships with companies or entities.